News

On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric antigen receptor (CAR)-T…
Read More...

Bicycle Therapeutics plc announced that Genentech, a member of the Roche Group, has exercised its second option to initiate a new program, expanding the exclusive strategic…
Read More...

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced that it has raised $50 million in a Series D financing round,…
Read More...

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that the U.S. Food and Drug…
Read More...

Thermo Fisher Scientific announced the launch of the Applied Biosystems TaqPath Respiratory Viral Select Panel; a CE-IVD-marked molecular assay panel for detection of five common…
Read More...

Innoviva, Inc. and La Jolla Pharmaceutical Company announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla. Innoviva has agreed to pay…
Read More...

Arcutis Biotherapeutics, Inc. announced that Health Canada has accepted for review the New Drug Submission (NDS) for roflumilast cream 0.3% for the treatment of plaque psoriasis in…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company…
Read More...

WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology…
Read More...

ADC Therapeutics SA announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi) for the development and commercialization of ZYNLONTA for all…
Read More...

Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine,…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) expanding the labeling to include…
Read More...

Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing…
Read More...

BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to…
Read More...

Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, and TSB…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio (mosunetuzumab),…
Read More...

Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center (“Moffitt”), a…
Read More...

Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with…
Read More...

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed…
Read More...

CureVac N.V. announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to…
Read More...